Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FXR0906 in Healthy Adult Participants With or Without Elevated Triglycerides
NCT07766759Phase 1Not yet recruiting
- Sponsor
- Fosun Pharma
- Start
- Aug 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FXR0906 in hypertriglyceridemia (3 arms), sponsored by Fosun Pharma. Primary endpoint: Safety and tolerability at 26 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
FXR0906
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT07766759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07766759.